Amylyx Pharmaceuticals Inc (AMLX NASDAQ) stock market data APIs
$3.56
-0.04(-1.1%)
as of January 24, 2025
Amylyx Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Prev. Close
3.6
Open
3.56
Volume
806 K
High
3.6494
Low
3.45
52 wk Range
1.575-19.949
Market Cap
308 M
Shares Outstanding
85 691 K
Revenue
196 M
EPS
-1.07
Beta
-0.699
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amylyx Pharmaceuticals Inc data using free add-ons & libraries
Get Amylyx Pharmaceuticals Inc Fundamental Data
Amylyx Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 196 M
- EBITDA: -248 247 008
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.915
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amylyx Pharmaceuticals Inc News
New
Analysts on Wall Street Lower Ratings for These 10 Stocks
In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These...
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong. In fact, since bottoming out around 1,650 in ...
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the qua...
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
